Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression: a Systematic Review
Ana Malta Gomes, Filipa Novais
Current Treatment Options in Psychiatry May 5, 2025 DOI: 10.1007/s40501-025-00346-z (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Sample size | 421 |
| Population | Patients with treatment-resistant depression |
| Interventions | Ketamine-assisted psychotherapy Ketamine monotherapy |
| Topics | Depression Ketamine Esketamine Psychedelic-assisted therapy |
| Keywords | Neurology Depression economics Psychotherapist Cognition |
| Citations | 3 |
| Key findings | Ketamine-assisted psychotherapy significantly reduces depressive symptoms in treatment-resistant depression compared to ketamine monotherapy, though methodological limitations prevent definitive conclusions. |
Abstract
Abstract Purpose of the review Treatment-resistant depression (TRD) is a challenging condition characterized by minimal improvement despite two or more antidepressant trials. Ketamine-assisted psychotherapy (KAP) integrates the rapid antidepressant effects of ketamine with psychotherapy to enhance and sustain therapeutic outcomes. This systematic review evaluates the effectiveness of KAP in reducing depressive symptoms in TRD compared to ketamine monotherapy. Recent findings Eight studies, including 421 participants, were analyzed, highlighting significant reductions in depressive symptoms with KAP. Preliminary evidence suggests that KAP may also alleviate comorbid conditions such as PTSD, anxiety, and chronic pain. However, methodological limitations, including small sample sizes and variability in intervention protocols, restrict the ability to draw definitive conclusions. Risk of bias and short follow-up durations were common across studies. Summary KAP shows promise as an effective intervention for TRD, potentially enhancing the antidepressant effects of ketamine. Despite these encouraging findings, the variability in study designs and limited long-term data emphasize the need for larger, high-quality trials to confirm its efficacy and establish standardized protocols.